Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Review, H1 2015

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Review, H1 2015', provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 9

Therapeutics Development 10

Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS)-Overview 10

Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS)-Comparative Analysis 11

Cognitive Impairment Associated With Schizophrenia (CIAS)-Therapeutics under Development by Companies 12

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Cognitive Impairment Associated With Schizophrenia (CIAS)-Products under Development by Companies 18

Cognitive Impairment Associated With Schizophrenia (CIAS)-Companies Involved in Therapeutics Development 20

AbbVie Inc. 20

Amarantus Bioscience Holdings, Inc. 21

Avineuro Pharmaceuticals, Inc. 22

CoMentis, Inc. 23

Eli Lilly and Company 24

FORUM Pharmaceuticals Inc. 25

H. Lundbeck A/S 26

Intra-Cellular Therapies, Inc. 27

Iproteos S.L. 28

Merck & Co., Inc. 29

Mithridion, Inc. 30

Mnemosyne Pharmaceuticals, Inc. 31

Novartis AG 32

Pfizer Inc. 33

Saniona AB 34

Siena Biotech S.p.A. 35

SK Biopharmaceuticals Co., Ltd. 36

Sunovion Pharmaceuticals Inc. 37

Takeda Pharmaceutical Company Limited 38

Upsher-Smith Laboratories, Inc. 39

Cognitive Impairment Associated With Schizophrenia (CIAS)-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43

Assessment by Route of Administration 45

Assessment by Molecule Type 46

Drug Profiles 48

A-431404-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

ABT-126-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

AN-761-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AQW-051-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

AUT-1-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AVL-3288-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

AVN-211-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

BNC-375-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

CDD-0304-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

DSP-3748-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

eltoprazine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

encenicline hydrochloride-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

erteberel-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

GTS-21-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

IPR-001-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

IPR-088-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

ITI-214-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

LUAF-64280-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

PNU-120596-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

roflumilast-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

SEN-15924-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

SKL-15508-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecule to Agonize NMDA2B for CIAS-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Small Molecules for Cognitive Impairment Associated with Schizophrenia-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

TAK-058-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Cognitive Impairment Associated With Schizophrenia (CIAS)-Recent Pipeline Updates 82

Cognitive Impairment Associated With Schizophrenia (CIAS)-Dormant Projects 91

Cognitive Impairment Associated With Schizophrenia (CIAS)-Discontinued Products 93

Cognitive Impairment Associated With Schizophrenia (CIAS)-Product Development Milestones 94

Featured News & Press Releases 94

Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 94

Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor 94

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 96

Disclaimer 96

List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2015 10

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by AbbVie Inc., H1 2015 20

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 21

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Avineuro Pharmaceuticals, Inc., H1 2015 22

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by CoMentis, Inc., H1 2015 23

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Eli Lilly and Company, H1 2015 24

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 25

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by H. Lundbeck A/S, H1 2015 26

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 27

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Iproteos S.L., H1 2015 28

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Merck & Co., Inc., H1 2015 29

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Mithridion, Inc., H1 2015 30

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 31

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Novartis AG, H1 2015 32

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Pfizer Inc., H1 2015 33

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Saniona AB, H1 2015 34

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Siena Biotech S.p.A., H1 2015 35

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 36

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 37

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 38

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 39

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Stage and Target, H1 2015 42

Number of Products by Stage and Mechanism of Action, H1 2015 44

Number of Products by Stage and Route of Administration, H1 2015 45

Number of Products by Stage and Molecule Type, H1 2015 47

Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics-Recent Pipeline Updates, H1 2015 82

Cognitive Impairment Associated With Schizophrenia (CIAS)-Dormant Projects, H1 2015 91

Cognitive Impairment Associated With Schizophrenia (CIAS)-Dormant Projects (Contd..1), H1 2015 92

Cognitive Impairment Associated With Schizophrenia (CIAS)-Discontinued Products, H1 2015 93

List of Figures

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2015 10

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Top 10 Targets, H1 2015 41

Number of Products by Stage and Top 10 Targets, H1 2015 42

Number of Products by Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45

Number of Products by Top 10 Molecule Types, H1 2015 46

Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Amarantus Bioscience Holdings, Inc.

Avineuro Pharmaceuticals, Inc.

CoMentis, Inc.

Eli Lilly and Company

FORUM Pharmaceuticals Inc.

H. Lundbeck A/S

Intra-Cellular Therapies, Inc.

Iproteos S.L.

Merck & Co., Inc.

Mithridion, Inc.

Mnemosyne Pharmaceuticals, Inc.

Novartis AG

Pfizer Inc.

Saniona AB

Siena Biotech S.p.A.

SK Biopharmaceuticals Co., Ltd.

Sunovion Pharmaceuticals Inc.

Takeda Pharmaceutical Company Limited

Upsher-Smith Laboratories, Inc.

Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutic Products under Development, Key Players in Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Overview, Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline, Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com